Beyer Anne, Baumann Sven, Scherz Gesine, Stahl Jessica, von Bergen Martin, Friese Anika, Roesler Uwe, Kietzmann Manfred, Honscha Walther
University Leipzig, Faculty of Veterinary Medicine, Institute of Pharmacology, Pharmacy and Toxicology, Leipzig, Germany.
Helmholtz Centre for Environmental Research - UFZ, Department of Metabolomics, Leipzig, Germany.
BMC Vet Res. 2015 Oct 15;11:265. doi: 10.1186/s12917-015-0578-3.
Healthy farm animals have been found to act as a reservoir of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (E. coli). Therefore, the objective of the study was to determine the input of antimicrobial active ceftiofur metabolites in the stable via faeces and urine after intramuscular administration of the drug to pigs and the elucidation of the Escherichia coli ESBL resistance pattern of treated and untreated pigs housed in the same barn during therapy.
For determination of the minimal inhibitory concentration (MIC) the method of microdilutionaccording to the recommended procedure of the Clinical and Laboratory Standards Institute was used. Inaddition to that, a qualitative determination was performed by agar dilution. Unsusceptible E. coli speciesselected via agar dilution with cefotaxime were confirmed by MALDI-TOF and ESBL encoding genes wereidentified by PCR. The amounts of ceftiofur measured as desfuroylceftiofur (DFC) in the different probes (plasma, urine, faeces and dust) were analysed by UPLC-MS/MS.
In a first experiment two groups of pigs (6 animals per group) were housed in the same barn in two separated boxes. One group (group B) were treated with ceftiofur according to the licence (3 mg/kg administered intramuscularly (i.m.) on three consecutive days, day 1-3). During a second treatment period (day 29-31) an increased rate of ESBL resistant E. coli was detectable in these treated pigs and in the air of the stable. Moreover, the second group of animals (group A) formerly untreated but housed for the whole period in the same stable as the treated animals revealed increased resistance rates during their first treatment (day 45-47) with ceftiofur. In order to investigate the environmental input of ceftiofur during therapy and to simulate oral uptake of ceftiofur residues from the air of the stable a second set of experiments were performed. Pigs (6 animals) were treated with an interval of 2 weeks for 3 days with different doses of ceftiofur (3 mg/kg, 1 mg/kg and 0.3 mg/kg i.m.) as well as with 3 mg/kg per os) and the renal and biliary excretion of ceftiofur as its active metabolite were measured in comparison to the plasma levels. In addition to that, probes of the sedimentation dust and the air of the stable were analysed for drug residues.
The present study shows that treatment of several animals in a stable with ceftiofur influences the resistance pattern of intestinal Escherichia coli of the treated as well as untreated animals housed in the same stable. During therapy with the drug which was administered by injection according to the licence we detected nameable amounts of ceftiofur and its active metabolites in the dust and air of the stable.
已发现健康的农场动物是产超广谱β-内酰胺酶(ESBL)的大肠杆菌(E. coli)的储存宿主。因此,本研究的目的是确定给猪肌肉注射药物后,通过粪便和尿液进入猪舍的抗菌活性头孢噻呋代谢物的输入量,并阐明治疗期间饲养在同一猪舍的经治疗和未经治疗的猪的大肠杆菌ESBL耐药模式。
采用根据临床和实验室标准协会推荐程序进行的微量稀释法测定最低抑菌浓度(MIC)。此外,通过琼脂稀释法进行定性测定。通过头孢噻肟琼脂稀释法选择的不敏感大肠杆菌菌株经基质辅助激光解吸电离飞行时间质谱(MALDI-TOF)确认,通过聚合酶链反应(PCR)鉴定ESBL编码基因。采用超高效液相色谱-串联质谱(UPLC-MS/MS)分析不同样本(血浆、尿液、粪便和灰尘)中以去呋喃甲酰头孢噻呋(DFC)计的头孢噻呋含量。
在第一个实验中,两组猪(每组6只)饲养在同一猪舍的两个分开的栏中。一组(B组)按照许可剂量用头孢噻呋治疗(连续三天,第1 - 3天,肌肉注射3 mg/kg)。在第二个治疗期(第29 - 31天),在这些经治疗的猪以及猪舍空气中可检测到产ESBL大肠杆菌的比例增加。此外,另一组动物(A组)之前未接受治疗,但在整个期间与经治疗的动物饲养在同一猪舍,在其首次用头孢噻呋治疗(第45 - 47天)期间显示出耐药率增加。为了研究治疗期间头孢噻呋的环境输入,并模拟从猪舍空气中口服摄取头孢噻呋残留,进行了第二组实验。猪(6只)每隔2周治疗3天,分别给予不同剂量的头孢噻呋(3 mg/kg、1 mg/kg和0.3 mg/kg肌肉注射)以及3 mg/kg口服),并与血浆水平比较,测定头孢噻呋作为其活性代谢物的肾排泄和胆汁排泄。此外,分析猪舍沉降灰尘和空气样本中的药物残留。
本研究表明,在猪舍中用头孢噻呋治疗多只动物会影响同一猪舍中经治疗和未经治疗动物肠道大肠杆菌的耐药模式。在按照许可通过注射给药治疗期间,我们在猪舍的灰尘和空气中检测到了可观量的头孢噻呋及其活性代谢物。